Form 4: Vertex Pharmaceuticals EVP Tatsis Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 3,242 shares of common stock at $499.99 per share on March 10, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Ourania Tatsis, an Executive Vice President and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, sold 3,242 shares of the company's common stock on March 10, 2025.
- The sale was executed at a price of $499.99 per share.
- The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1, which was established on November 22, 2024.
- Following the sale, Tatsis directly owns 51,239 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by executives are a normal part of executive compensation and wealth management. The use of 10b5-1 plans allows insiders to sell shares without being accused of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the existence of the 10b5-1 trading plan.
Key Dates
| Date | Description |
|---|---|
| 11/22/2024 | Date of entry into Rule 10b5-1 trading plan |
| 03/10/2025 | Date of stock sale transaction |
| 03/12/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.